驱动基因阴性不可切除Ⅲ期非小细胞肺癌的转化治疗OA
Conversion therapy for initially unresectable stage Ⅲ non-small cell lung cancer without driver gene
肺癌是我国发病率及病死率最高的恶性肿瘤之一.部分患者在初诊时,已丧失根治性手术机会,临床常将其归为局部晚期不可切除非小细胞肺癌(non-small cell lung cancer,NSCLC),该类患者远期预后仍然不理想.尤其对于驱动基因阴性人群,因缺乏有效的分子靶向治疗策略,其预后更为严峻.近年来,随着免疫治疗应答率的显著提升,部分初始评估为局部晚期不可切除NSCLC患者经诱导治疗后有望获得转化手术的机会.针对驱动基因阴性且初始不可切除NSCLC是否应行转化手术,临床争议尚存.美国胸外科医师协会(STS)专家共识明确此类患者不宜实施诱导治疗,但随着免疫治疗疗效显著提升,越来越多的研究开始探索该策略,并已观察到初步生存获益.本文拟从不可切除状态的定义、治疗策略的演进历程及转化治疗所涉及的核心问题等层面,系统阐述转化治疗作为驱动基因阴性不可切除NSCLC标准治疗补充策略的潜在价值与现实意义.
Lung cancer remains one of the malignancies with the highest incidence and mortality rates in China.A substantial proportion of patients are diagnosed as unresectable at initial presentation and are consequently categorized as locally advanced unresectable non-small cell lung cancer(NSCLC),a subgroup characterized by suboptimal long-term prognosis.This is particularly pronounced for patients with negative driver gene mutations,who face an even grimmer prognosis due to the absence of effective molecular targeted therapy.In recent years,with the remarkable improvement in response rates to immunotherapy,a subset of patients initially diagnosed with locally advanced unresectable NSCLC may become eligible for conversion surgery following induction therapy.Whether conversion surgery should be implemented for patients with driver gene-negative unresectable NSCLC remains a topic of extensive clinical debate.The Society of Thoracic Surgeons(STS)expert consensus explicitly discourages induction therapy administered solely for the purpose of downstaging tumors to achieve surgical resectability in this patient population.Nevertheless,with the significant improvement in the antitumor efficacy of immunotherapy,a growing body of research has begun to investigate this therapeutic strategy and has reported preliminary survival benefits.In this review,we aim to systematically elaborate on the potential value and clinical significance of conversion therapy as a complementary approach to standard treatment for unresectable driver gene-negative NSCLC,focusing on three core dimensions:the definition of unresectability,the evolution of treatment paradigms,and key unresolved issues related to conversion therapy.
国灏;张嘉涛;贲晓松;杨学宁
南方医科大学附属广东省人民医院(广东省医学科学院)广东省肺癌研究所(广东 广州 510080)南方医科大学附属广东省人民医院(广东省医学科学院)广东省肺癌研究所(广东 广州 510080)南方医科大学附属广东省人民医院(广东省医学科学院)胸外科(广东 广州 510080)南方医科大学附属广东省人民医院(广东省医学科学院)广东省肺癌研究所(广东 广州 510080)
医药卫生
转化手术局部晚期不可切除肺癌非小细胞肺癌驱动基因阴性
conversion surgerylocally advancedunresectable lung cancernon-small cell lung cancerdriver gene-negative
《实用医学杂志》 2026 (19)
3479-3485,7
评论